Kymriah Demonstrates a Favorable Safety Profile in FL; Updated Results for AUTO1's Ph1 ALLCAR19 Trial in ALL and iNHL; Initial Data from Cellectis's UCART22 Ph1 BALLI-01 Study; ASH Day 1 Encore
Here is a brief preview of this blast: On the first day of ASH 2020, three key clinical updates were presented from Novartis, Autolus, and Cellectis. Below, Celltelligence provides insights and context for each presentation.